OM Pharma SA

Paediatric respiratory infections

OM Pharma SA’s clinical research includes recurrent respiratory tract infections in young children, with attention to wheezing lower respiratory illness and infection-related respiratory morbidity.

  • Recurrent respiratory tract infections
  • Wheezing lower respiratory illness
  • Paediatric respiratory disease

The sponsor’s studies in this area focus on childhood respiratory conditions where infection and wheezing overlap clinically.

Recurrent wheezing

Another key area of interest is recurrent wheezing in infants and young children, reflecting a focus on early-life respiratory symptoms and their persistence over time.

  • Recurrent wheezing
  • Infant respiratory symptoms
  • Childhood airway reactivity

Research activity in this domain addresses repeated wheezing episodes in a paediatric population with ongoing respiratory vulnerability.

Allergic asthma

The sponsor also funds work in mild allergic asthma, indicating interest in inflammatory airway disease and allergy-associated respiratory impairment.

  • Mild allergic asthma
  • Allergic airway inflammation
  • Asthma in healthy volunteers and patients

This area links respiratory allergy with clinical evaluation of tolerability and safety in people affected by mild asthma.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on OM-85 for Preventing Respiratory Infections in Children with Wheezing Illness (Ages 6 Months to 5 Years)

    Not recruiting

    1 1 1
    Germany Hungary Italy Poland
  • Study on the Effectiveness and Safety of OM-85 for Children Aged 6 Months to 5 Years with Recurrent Wheezing

    Not recruiting

    1 1
    Hungary Poland